Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans

• Published in: Current hypertension reports Vol. 3 Suppl 2; no. S2; pp. S22 - S27
• Main Authors: Vesterqvist, O, Reeves, R A
• Format: Journal Article
• Language: English
• Published: United States Springer Nature B.V 01.12.2001
• Subjects: Angiotensin-Converting Enzyme Inhibitors - pharmacology; Animals; Antihypertensive Agents - pharmacology; Atrial Natriuretic Factor - drug effects; Biomarkers; Blood pressure; Blood Pressure - drug effects; Drug therapy; Enzymes; Humans; Hypertension; Hypertension - drug therapy; Neprilysin - antagonists & inhibitors; Pyridines - pharmacology; Renin-Angiotensin System - drug effects; Thiazepines - pharmacology; Vasodilator Agents - pharmacology
• ISSN: 1522-6417; 1534-3111
• DOI: 10.1007/s11906-001-0103-x

Vasopeptidase inhibition is a new concept in blood pressure management. A single molecule simultaneously inhibits two enzymes that regulate cardiovascular function: neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE)[1]. Development of vasopeptidase inhibitors stemmed from the need for new and more efficacious antihypertensive agents that not only reduce blood pressure but also treat hypertension as part of a larger syndrome involving endothelial dysfunction [2]. By inhibiting NEP and ACE, vasopeptidase inhibitors enhance the natriuretic peptide and kallikrein-kinin systems and inhibit the renin-angiotensin-aldosterone system. This article outlines the pharmacodynamic effects of the vasopeptidase inhibitor omapatrilat on biomarkers of NEP and ACE activity in humans.